Research & Development
Grifols partners with BARDA to develop treatment for sulfur mustard eye injury
22 October 2024 -

Spanish healthcare company Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ:GRFS), a manufacturer of plasma-derived medicines, announced on Tuesday that it has partnered with the Biomedical Advanced Research and Development Authority (BARDA) to develop a treatment for sulfur mustard-induced eye injury.

The treatment uses ocular surface immunoglobulin (OSIG) eye drops to neutralize symptoms caused by the chemical warfare agent.

If successful, the preclinical study could lead to US Food and Drug Administration (FDA) approval for the first medical treatment for sulfur mustard ocular injury.

Grifols is also developing an OSIG treatment for dry eye disease, which is expected to enter clinical trials in 2025.

Login
Username:

Password: